Skip to content

PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men

PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05353283
Acronym
PrEP2-BAY
Enrollment
63
Registered
2022-04-29
Start date
2023-09-01
Completion date
2025-07-01
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk Reduction

Keywords

PrEP, Young MSM, POC monitoring, adherence, motivational interviewing, urine test, tenofovir

Brief summary

Despite advances in HIV prevention, the HIV incidence among young men who have sex with men (YMSM) is increasing, threatening to derail achievement of the United States End the HIV Epidemic goals. Although, pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method, adherence was sufficiently low to comprise efficacy among a high proportion of YMSM in multiple clinical trials and demonstration projects. In this study, the investigators will leverage a novel urine point-of-care drug-level test for PrEP adherence, to both enhance and target motivational-interviewing-based adherence counseling among YMSM, with the goal of preventing HIV infections among this critically at-risk group.

Detailed description

Young men who have sex with men (YMSM; ages 15-29 years) have rising HIV incidence in the United States. Pre-exposure prophylaxis (PrEP) is a highly effective medication prevent HIV infection, both at the individual and population level. However, in several clinical trials and demonstration projects among YMSM, a majority of participants had adherence to PrEP sufficiently low to compromise efficacy throughout the study. Unfortunately, pill-counts and self-reported adherence have limitations in this population, and therapeutic drug monitoring using previously available methods requires expensive equipment and specialized staff, meaning it cannot be implemented at the point-of-care (POC). The investigators have developed a novel POC test to measure urine drug-levels to PrEP for the first time, providing the opportunity to target and enhance adherence counseling during a routine clinical visit. Substantial knowledge gaps on the correct counseling approach and framing of the drug-level feedback message must be addressed to use this strategy to improve adherence among YMSM. This study will use a mixed methods approach to test the central hypothesis that an intervention leveraging a POC urine bioassay to detect PrEP adherence can both target and enhance adherence counseling. Brief interventions are a motivational interviewing (MI) counseling approach with wide uptake by primary care providers for substance use prevention and medical therapy adherence. PrEP2-BAY proposes a brief intervention be used as the framework for POC drug-level feedback among YMSM using PrEP. This study will test the acceptability, feasibility, and preliminary impact on long-term adherence, measured through hair tenofovir levels, of the brief intervention in a pilot randomized controlled trial among YMSM. This proposed research plan has the goal of optimizing PrEP's impact through a novel adherence support intervention. The findings of this proposal will lead to a R01 application to test a POC bioassay-enhanced adherence brief intervention among YMSM in a multi-city trial, with the goal of reducing the burden of HIV among MSM.

Interventions

BEHAVIORALMotivational Interviewing Counselling

Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test

DEVICEPoint-of-care Urine Tenofovir Measurement

Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.

Sponsors

University of California, San Francisco
Lead SponsorOTHER
University of Miami
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Male sex at birth who has sex with men * Age 18-30 years-old * Currently receiving tenofovir-based oral PrEP * Plans to continue taking daily PrEP over the upcoming 3 months

Exclusion criteria

* Participant living with HIV * Age \> 30 years

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Indicating the Intervention Was Acceptable3 monthsNumber of participants reporting the intervention to be "somewhat" or "very" acceptable on a five-point Likert scale

Secondary

MeasureTime frameDescription
Long-term Adherence Outcomes3 monthsMeasure change in tenofovir levels in hair samples from baseline to 3 months using liquid chromatography-mass spectrometry assays.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMatthew Spinelli, MD, MAS

University of California, San Francisco

Participant flow

Recruitment details

Participants were recruited via targeted advertisements on a geospatial social mobile application.

Pre-assignment details

63 participants were enrolled and randomized.

Baseline characteristics

Characteristic
Age, Continuous26.1 Years
STANDARD_DEVIATION 2.7
Daily PrEP Regimen
Descovy (FTC/TAF)
8 Participants
Daily PrEP Regimen
Truvada (FTC/TDF)
32 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
14 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
39 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
8 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
23 Participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 420 / 21
other
Total, other adverse events
0 / 420 / 21
serious
Total, serious adverse events
0 / 420 / 21

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026